These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 8232934)
41. Features associated with the development of hallucinations in Parkinson's disease. Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542 [TBL] [Abstract][Full Text] [Related]
42. Cognitive correlates of visual hallucinations in non-demented Parkinson's disease patients. Hepp DH; da Hora CC; Koene T; Uitdehaag BM; van den Heuvel OA; Klein M; van de Berg WD; Berendse HW; Foncke EM Parkinsonism Relat Disord; 2013 Sep; 19(9):795-9. PubMed ID: 23706540 [TBL] [Abstract][Full Text] [Related]
43. [Cost reduction in long-term nursing thanks to a memory clinic--results of a case control study]. Wettstein A; Bieri G; Ganzoni V; Hafner M; Hanhart U; Meier A; Pachmann A; Schlatter I; Schmid R; Schoeller E; Schönenberger PM; Zink R; Zumsteg S Praxis (Bern 1994); 1996 Sep; 85(38):1175-9. PubMed ID: 8927896 [TBL] [Abstract][Full Text] [Related]
44. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Fernandez HH; Lapane KL Med Sci Monit; 2002 Apr; 8(4):CR241-6. PubMed ID: 11951064 [TBL] [Abstract][Full Text] [Related]
45. Visual complaints and visual hallucinations in Parkinson's disease. Urwyler P; Nef T; Killen A; Collerton D; Thomas A; Burn D; McKeith I; Mosimann UP Parkinsonism Relat Disord; 2014 Mar; 20(3):318-22. PubMed ID: 24405755 [TBL] [Abstract][Full Text] [Related]
46. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
47. Diagnostic accuracy of Parkinson's disease and atypical parkinsonism in nursing homes. Weerkamp NJ; Tissingh G; Poels PJ; Zuidema SU; Munneke M; Koopmans RT; Bloem BR Parkinsonism Relat Disord; 2014 Nov; 20(11):1157-60. PubMed ID: 25258327 [TBL] [Abstract][Full Text] [Related]
48. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. Tse W; Frisina PG; Hälbig TD; Gracies JM; Liang L; Tarshish C; Lesser G; Neufeld R; Koller WC; Libow LS J Am Med Dir Assoc; 2008 Nov; 9(9):670-5. PubMed ID: 18992700 [TBL] [Abstract][Full Text] [Related]
49. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. Barnes J; David AS J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):727-33. PubMed ID: 11385004 [TBL] [Abstract][Full Text] [Related]
50. Epidemiology of psychosis in Parkinson's disease. Fénelon G; Alves G J Neurol Sci; 2010 Feb; 289(1-2):12-7. PubMed ID: 19740486 [TBL] [Abstract][Full Text] [Related]
51. Revealing regional differences in the institutionalization of adult patients in homes for the elderly and nursing homes: results of the Belgian network of sentinel GPs. Devroey D; Van Casteren V; De Lepeleire J Fam Pract; 2001 Feb; 18(1):39-41. PubMed ID: 11145626 [TBL] [Abstract][Full Text] [Related]
52. [Psychotic symptoms in Parkinson's disease]. Fénelon G Psychol Neuropsychiatr Vieil; 2006 Dec; 4 Spec No 1():S17-24. PubMed ID: 23631044 [TBL] [Abstract][Full Text] [Related]
53. Telemedicine for the care of nursing home residents with Parkinson's disease. Biglan KM; Voss TS; Deuel LM; Miller D; Eason S; Fagnano M; George BP; Appler A; Polanowicz J; Viti L; Smith S; Joseph A; Dorsey ER Mov Disord; 2009 May; 24(7):1073-6. PubMed ID: 19353687 [TBL] [Abstract][Full Text] [Related]
54. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson's disease. Rodríguez-Violante M; Cervantes-Arriaga A; Villar-Velarde A; Corona T Neurologia; 2011; 26(6):319-24. PubMed ID: 21315490 [TBL] [Abstract][Full Text] [Related]
55. The impact of respite use on nursing home placement. Kosloski K; Montgomery RJ Gerontologist; 1995 Feb; 35(1):67-74. PubMed ID: 7890206 [TBL] [Abstract][Full Text] [Related]
56. REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: a two-year follow up. Sinforiani E; Pacchetti C; Zangaglia R; Pasotti C; Manni R; Nappi G Mov Disord; 2008 Jul; 23(10):1441-5. PubMed ID: 18512749 [TBL] [Abstract][Full Text] [Related]
57. Assessment of hallucinations in Parkinson's disease using a novel scale. Wada-Isoe K; Ohta K; Imamura K; Kitayama M; Nomura T; Yasui K; Nakaso K; Nakashima K Acta Neurol Scand; 2008 Jan; 117(1):35-40. PubMed ID: 18095953 [TBL] [Abstract][Full Text] [Related]
58. Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease. Bannier S; Berdagué JL; Rieu I; de Chazeron I; Marques A; Derost P; Ulla M; Llorca PM; Durif F J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):1019-21. PubMed ID: 22752694 [TBL] [Abstract][Full Text] [Related]
59. Prospective analysis of risk factors for nursing home placement of dementia patients. Smith GE; O'Brien PC; Ivnik RJ; Kokmen E; Tangalos EG Neurology; 2001 Oct; 57(8):1467-73. PubMed ID: 11673591 [TBL] [Abstract][Full Text] [Related]
60. Risk factors for visual hallucinations in patients with Parkinson's disease. Gama RL; de Bruin VM; de Bruin PF; Távora DG; Lopes EM; Jorge IF; Bittencourt LR; Tufik S Neurol Res; 2015 Feb; 37(2):112-6. PubMed ID: 25002179 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]